A Phase 2 interventional study of Lidocaine and Placebo in Dysmenorrhea, sponsored by Juniper Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-17.
Sponsored by Juniper Pharmaceuticals, Inc. · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Dysmenorrhea with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Dysmenorrhea · United States.
Among the 68 studies in Dysmenorrhea with a site in United States, this one is the 30th largest by enrollment of the 62 interventional ones that give a count, is one of 2 that started in 2007, is one of 12 in phase 2, and was the 9th registered.
432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.
Browse Dysmenorrhea studies →9 of the 68 studies in Dysmenorrhea with a site in United States are open now. Recruiting first, the newest first:
Samphire Group, Inc. · Sites in United States
Ages 18–65 · Women only · Healthy volunteers
Western University of Health Sciences · Sites in United States
Ages 20–51 · Women only
Helaina Inc. · Sites in United States
Ages 18–40 · Women only · Healthy volunteers
Samphire Group, Inc. · Sites in United States
Ages 22–45 · Women only
Zenchi, Inc. · Sites in United States
Ages 20–45 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 16 · Phase 4 8
First in 2004; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is above the median of 62 across 364 interventional studies indexed under Dysmenorrhea.
Median enrollment 73 across the 62 interventional studies, 291 across the 5 observational. Of the 51 that completed or were terminated, 21 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 68 have an industry lead sponsor. The 10 most frequent:
Juniper Pharmaceuticals, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Juniper Pharmaceuticals, Inc. has 1 study filed under Dysmenorrhea — fewer than ten, so there is no comparison to draw.
4 of the studies in Dysmenorrhea with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04333576Phase 3AbbVieStudy Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | 2027-07 |
| NCT07524270Helaina Inc.Effera Dose Response: Women's Health | 2026-11 |
| NCT07679074Samphire Group, Inc.CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life | 2027-01-01 |
| NCT07508358Kevin HellmanVaginal Sildenafil for Primary Dysmenorrhea | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 68 studies in Dysmenorrhea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether lidocaine vaginal gel is safe and effective for preventing or reducing the severity of dysmenorrhea (painful menstrual periods) compared to placebo (inactive gel).
The primary objective of this study is to evaluate the efficacy of 10% (150 mg) lidocaine gel compared with placebo in reducing the severity and onset of primary dysmenorrhea in women with recurrent dysmenorrhea.
The secondary objectives of this study are the following:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lidocaine 10% (150mg) vaginal gel
Drug: Lidocaine
Placebo vaginal gel
Drug: Placebo
Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days
Placebo vaginal gel administered once daily for 4 days
The Primary Efficacy Variable Will be the Time-weighted Average Pain Intensity Over 4 Treatment Days Using the 4 Point Categorical Scale.
Time frame: Two 4-day dosing regimens for two consecutive monthy menstrual cycles
Treatment-emgergent Adverse Events
Time frame: approximately two months, based on onset of menses
Evaluate Electrocardiograms (ECGs) for Potentially Significant QT Changes at Approximate Peak Lidocaine Plasma Concentration After 4 Days of Dosing
Time frame: 7 hours following fourth dose in 2 consecutive menstrual cycles
Clinics and private practice offices; 8/31/07-6/13/08. Maximum patient participation was approx 4 months, including 45 day screening period, a treatment period of approx 8 weeks duration (during which subjects received study drug on a total of 8 days), and a post treatment visit occurring 2 - 3 weeks after Treatment Cycle 2,Visit 5.
| Milestone | Active | Placebo |
|---|---|---|
| Started | 41 | 43 |
| Completed | 35 | 37 |
| Not completed | 6 | 6 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Adminstrative discontinuation | 2 | 3 |
| units on a scale | Lidocaine 10% | Placebo Gel |
|---|---|---|
| The Primary Efficacy Variable Will be the Time-weighted Average Pain Intensity Over 4 Treatment Days Using the 4 Point Categorical Scale. | 0.91 ± 0.635 | 0.92 ± 0.552 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active | — | 0/77 (0%) | 6/77 (7.8%) |
| Placebo | — | 0/77 (0%) | 7/77 (9.1%) |
| Event | Active | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 6/77 | 7/77 |
| Age, Categorical(Participants) | Active | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 41 | 43 | 84 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | Active | Placebo | Total |
|---|---|---|---|
| Mean | 26.5 ± 7.20 | 27.7 ± 6.69 | 27.1 ± 6.92 |
| Sex: Female, Male(Participants) | Active | Placebo | Total |
|---|---|---|---|
| Female | 41 | 43 | 84 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | Active | Placebo | Total |
|---|---|---|---|
| United States | 41 | 43 | 84 |
The record gives a start of Aug 2007, a primary completion of Jun 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine
Juniper Pharmaceuticals, Inc.